PURPOSE: To report outcome of HPV-related [HPV(+)] oropharyngeal cancer (OPC) managed predominantly by altered-fractionation radiotherapy-alone (RT-alone). METHODS: OPCs treated with RT-alone (n = 207) or chemoradiotherapy (CRT) (n = 151) from 2001 to 2008 were included. Overall survival (OS), local (LC), regional (RC) and distant (DC) control were compared for HPV(+) vs. HPV-unrelated [HPV(-)], by RT-alone vs. CRT, and by smoking pack-years (≤ 10 vs. >10). Multivariate analysis identified predictors. RESULTS: HPV(+) (n = 277) had better OS (81% vs. 44%), LC (93% vs. 76%), RC (94% vs. 79%) (all p < 0.01) but similar DC (89% vs. 86%, p = 0.87) vs. HPV(-) (n = 81). HPV(+) stage IV CRT (n = 125) had better OS (89% vs. 70%, p < 0.01), but similar LC (93% vs. 90%, p = 0.41), RC (94% vs. 90%, p = 0.31) and DC (90% vs. 83%, p = 0.22) vs. RT-alone (n = 96). Both HPV(+) RT-alone (n = 37) and CRT (n = 67) stage IV minimal smokers had favorable OS (86% vs. 88%, p = 0.45), LC (95% vs. 92%, p = 0.52), RC (97% vs. 93%, p = 0.22), and DC (92% vs. 86%, p = 0.37). RT-alone and heavy-smoking were independent predictors for lower OS but not CSS in multivariate analysis. CONCLUSIONS: Overall, HPV(+) RT-alone stage IV demonstrated lower survival but comparable disease control vs. CRT, but no difference was apparent among minimal smokers.
PURPOSE: To report outcome of HPV-related [HPV(+)] oropharyngeal cancer (OPC) managed predominantly by altered-fractionation radiotherapy-alone (RT-alone). METHODS: OPCs treated with RT-alone (n = 207) or chemoradiotherapy (CRT) (n = 151) from 2001 to 2008 were included. Overall survival (OS), local (LC), regional (RC) and distant (DC) control were compared for HPV(+) vs. HPV-unrelated [HPV(-)], by RT-alone vs. CRT, and by smoking pack-years (≤ 10 vs. >10). Multivariate analysis identified predictors. RESULTS: HPV(+) (n = 277) had better OS (81% vs. 44%), LC (93% vs. 76%), RC (94% vs. 79%) (all p < 0.01) but similar DC (89% vs. 86%, p = 0.87) vs. HPV(-) (n = 81). HPV(+) stage IV CRT (n = 125) had better OS (89% vs. 70%, p < 0.01), but similar LC (93% vs. 90%, p = 0.41), RC (94% vs. 90%, p = 0.31) and DC (90% vs. 83%, p = 0.22) vs. RT-alone (n = 96). Both HPV(+) RT-alone (n = 37) and CRT (n = 67) stage IV minimal smokers had favorable OS (86% vs. 88%, p = 0.45), LC (95% vs. 92%, p = 0.52), RC (97% vs. 93%, p = 0.22), and DC (92% vs. 86%, p = 0.37). RT-alone and heavy-smoking were independent predictors for lower OS but not CSS in multivariate analysis. CONCLUSIONS: Overall, HPV(+) RT-alone stage IV demonstrated lower survival but comparable disease control vs. CRT, but no difference was apparent among minimal smokers.
Authors: Frank Ziemann; Andrea Arenz; Stefanie Preising; Claus Wittekindt; Jens P Klussmann; Rita Engenhart-Cabillic; Andrea Wittig Journal: Am J Cancer Res Date: 2015-02-15 Impact factor: 6.166
Authors: Jeffrey M Vainshtein; Matthew E Spector; Jonathan B McHugh; Ka Kit Wong; Heather M Walline; Serena A Byrd; Christine M Komarck; Mohannad Ibrahim; Matthew H Stenmark; Mark E Prince; Carol R Bradford; Gregory T Wolf; Scott McLean; Francis P Worden; Douglas B Chepeha; Thomas Carey; Avraham Eisbruch Journal: Oral Oncol Date: 2014-02-22 Impact factor: 5.337
Authors: Douglas R Farquhar; Andrew J Coniglio; Maheer M Masood; Nicholas Lenze; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Adam M Zanation; Mark C Weissler; Andrew F Olshan; Siddharth Sheth; Trevor G Hackman Journal: Oral Oncol Date: 2020-05-31 Impact factor: 5.337
Authors: Natalie M Lowe; Jonathan M Bernstein; Kathleen Mais; Kate Garcez; Lip W Lee; Andrew Sykes; David J Thomson; Jarrod J Homer; Catharine M West; Nicholas J Slevin Journal: J Cancer Res Clin Oncol Date: 2017-12-08 Impact factor: 4.553
Authors: Vanessa Vanderdys; Amir Allak; Fadila Guessous; Mouadh Benamar; Paul W Read; Mark J Jameson; Tarek Abbas Journal: Mol Cancer Ther Date: 2017-08-24 Impact factor: 6.261
Authors: Mark E Zafereo; Li Xu; Kristina R Dahlstrom; Carlo A Viamonte; Adel K El-Naggar; Qingyi Wei; Guojun Li; Erich M Sturgis Journal: Oral Oncol Date: 2016-03-21 Impact factor: 5.337